
DIRECTORS AND SENIOR MANAGEMENT

DIRECTORS

Our Board consists of nine members, three of whom are independent non-executive Directors. The power and duties of our Board include convening shareholders' meetings and reporting our Board's work at shareholders' meetings, implementing resolutions passed at shareholders' meetings, determining our Group's business plans and investment plans, formulating our Group's annual budget and financial statements, formulating proposals for profit distributions and for the increase or reduction of share capital as well as exercising other powers, functions and duties as conferred by the Memorandum and Articles of Association. All our Directors have entered into service contracts or letters of appointment with our Group.

The following table sets forth information regarding our current Directors.

Name	Age	Position	Responsibilities	Director's Appointment Date
Mr. AN Yubao (安郁寶先生)	70	Chairman and executive Director	corporate strategic planning and overall business development of our Group	24 January 2011
Ms. LI Qian (黎倩女士)	48	Executive Director and chief executive officer	formulating and implementing our corporate strategies, overseeing our overall business development and production, marketing, developing products and implementing operation plans and participating in the day-to-day management of our business operations	24 December 2012
Professor ZHU Quan (朱荃教授)	73	Executive Director	developing products and participating in the day-to-day management of our business operations	24 December 2012
Mr. YOUNG Wai Po, Peter (楊惠波先生)	70	Non-executive Director	attending meetings of our Board to perform duties as a Board member, but not participating in the day-to-day management of our business operations	24 December 2012

DIRECTORS AND SENIOR MANAGEMENT

Name	Age	Position	Responsibilities	Director's Appointment Date
Mr. WANG Shunlong (王順龍先生)	49	Non-executive Director	attending meetings of our Board to perform duties as a Board member, but not participating in the day-to-day management of our business operations	24 December 2012
Mr. WANG Zi Han (王紫翰先生)	59	Non-executive Director	attending meetings of our Board to perform duties as a Board member, but not participating in the day-to-day management of our business operations	24 December 2012
Mr. SU Yuanfu (蘇元福先生)	67	Independent non-executive Director	attending meetings of our Board to perform duties as a Board member, chairman of our nomination committee and member of our remuneration committee	2 December 2013
Mr. FENG Zhongshi (馮仲實先生)	54	Independent non-executive Director	attending meetings of our Board to perform duties as a Board member, chairman of our remuneration committee and member of our audit committee	2 December 2013
Ms. CHENG Xinxin (成欣欣女士)	60	Independent non-executive Director	attending meetings of our Board to perform duties as a Board member, chairman of our audit committee and member of our nomination committee	2 December 2013

DIRECTORS AND SENIOR MANAGEMENT

Executive Directors

Mr. AN Yubao (安郁寶) (formerly known as Mr. AN Yushi (安郁室)), aged 70, is our chairman and an executive Director and a Controlling Shareholder. He was appointed as our Director with effect from 24 January 2011. He is also the chairman of GZ Consun, Consun (Inner Mongolia) and Kangyuan and a director and the legal representative of Consun Research. Mr. AN is primarily responsible for the overall management, operations, investment and the charting and reviewing of corporate directions and strategies of our Group.

Mr. AN has over 10 years of experience in medical education and approximately 17 years of experience in the business of the pharmaceutical industry. He has served various key positions, such as executive director, chairman and legal representative of GZ Consun since its establishment. Mr. AN served as the vice chairman of 廣東南方李錦記商貿信息中心 (Guangdong Southern Lee Kum Kee Commercial Information Centre) from November 1995 to February 1999. From July 1996 to December 1998, Mr. AN started his career in the pharmaceutical industry by serving as the chairman and legal representative of 廣東南方李錦記營養保健品有限公司 (Guangdong Southern Lee Kum Kee Nutrition Health Products Co., Ltd.) representing 中國人民解放軍第一軍醫大學 (the First Military Medical University of the People's Liberation Army of the PRC) as one of its shareholders. Mr. AN served as the minister and vice president respectively of 南方醫科大學 (原中國人民解放軍第一軍醫大學) (Southern Medical University) (formerly known as the First Military Medical University of the People's Liberation Army of the PRC) from November 1991 to August 2001 and served as the vice president of 中國人民解放軍濟南軍區總醫院 (Jinan Military General Hospital) from 1987 to 1988. Between 1981 and 1987, Mr. AN worked at various units of the PRC People's Liberation Army and was mainly responsible for hygiene and hospital management.

Mr. AN graduated from 中國人民解放軍後勤學院 (the Logistics College of the PRC People's Liberation Army of the People's Liberation Army of the PRC) in 1981 and majored in commanding. Mr. AN also obtained a master's degree in business administration from Asia International Open University (Macau) (now known as City University of Macau) in November 2007.

Mr. AN served as the chairman of GZ Consun representing the First Military Medical University of the People's Liberation Army of the PRC when GZ Consun was established jointly by Cannopus (beneficially owned and controlled by Mr. YOUNG since the date of its incorporation) and the First Military Medical University of the People's Liberation Army of the PRC in December 1997. Mr. AN has known Mr. YOUNG as business acquaintance since 1993, while he has known Ms. LI since they were colleagues at the First Military Medical University of the People's Liberation Army of the PRC in 1991.

Mr. AN once served as the chairman and legal representative of 珠海經濟特區方洲醫藥科技發展有限公司 (Zhuhai Special Economic Zone Fangzhou Pharmaceutical Technology Development Co., Ltd.), a company incorporated in the PRC. The business license of this company was revoked by 珠海市工商行政管理局 (Zhuhai City Administration of Industry and Commerce) in September 2003 due to the failure of the shareholders to make further capital conduction after the first installment thereof. To the best of Mr. AN's knowledge, information and belief and having made all reasonable enquiry, Mr. AN confirmed that there is no contingent liabilities in respect of the above company and the revocation of its business licence. As confirmed by our PRC Legal Advisers, Mr. AN has no contingent liability in respect of the revocation of business license of above company.

Ms. LI Qian (黎倩), aged 48, is our executive Director and chief executive officer and a Controlling Shareholder. Ms. LI joined our Group in April 1998 as the associate director of general manager's office of GZ Consun. She was appointed as our Director with effect from 24 December

DIRECTORS AND SENIOR MANAGEMENT

2012. Ms. LI has also served as a director and the general manager (which was redesignated as president in May 2008) of GZ Consun since November 1999, a director of Consun Medicine since November 2003, a director of Consun (Inner Mongolia) since December 2005 and a director of Kangyuan since October 2009. Ms. LI is primarily responsible for formulating and implementing the corporate strategies, overseeing production activities, business development, research and administrative management of our Group.

Ms. LI has over 8 years of experience in medical education and 15 years of experience in the business of pharmaceutical industry. Prior to joining our Group, Ms. LI worked at Southern Medical University, formerly known as the First Military Medical University of the People's Liberation Army of the PRC between October 1989 and April 1998.

Ms. LI obtained a master's degree in business administration at Asia International Open University (Macau) (now known as City University of Macau) in November 2007. Ms. LI was granted the award of 優秀民營企業家 (Excellent Private Entrepreneur) by Tongliao City People's Government of the PRC in July 2008, was recognised as Model Worker (勞動模範) by Inner Mongolia People's Government of the PRC in April 2010 and was recognised as 廣東省醫藥行業著名企業家 (Famous Entrepreneur in Pharmaceutical Industry of Guangdong Province) by 廣東省醫藥行業協會 (Guangdong Province Pharmaceutical Industry Association) in December 2011. She has been appointed as a member of 第一屆中國女醫師協會腎臟病及血液淨化專家委員會 (First Expert Committee for Kidney Disease and Blood Purify of China Medical Women's Association) since March 2012. Ms. LI is also a local registered pharmacist of Guangdong province (廣東省駐店藥師) recognised by 廣東省食品藥品監督管理局 (Guangdong Province Food and Drug Administration).

Professor ZHU Quan (朱荃), aged 73, is our executive Director. He was appointed as our Director with effect from 24 December 2012. Professor ZHU is also a director and the chief scientist of GZ Consun, a director of Kangyuan and the general manager of Consun Research. Professor ZHU joined our Group in August 2006 as the chief scientist of GZ Consun. Professor ZHU is primarily responsible for the product research and development of our Group.

Professor ZHU has over 30 years of experience in teaching and research at medical school and 6 years of experience in the business of pharmaceutical industry. Professor ZHU has served as professor and Ph.D. candidate supervisor at 澳門科技大學 (Macau University of Science and Technology) since September 2003. He served various positions, such as a deputy director of medicine department, a director of 國家規範化中藥藥理實驗室 (National Standardization Laboratory for Chinese Herbal Pharmacology), a Ph.D. candidate supervisor at 南京中醫藥大學 (Nanjing University of Chinese Medicine) between October 1981 and November 2005. Professor ZHU also served as an expert for 國家教育部科學技術委員會 (Science & Technology Commission of Ministry of Education), an assessment expert for 國家自然科學基金生命科學部 (the Life Science Department of National Natural Science Foundation) and a drug evaluation expert in Jiangsu Province and in the PRC.

Professor ZHU graduated from 中醫科學院 (China Academy of Traditional Chinese Medicine) (now known as 中國中醫科學院 (China Academy of Chinese Medical Sciences)) in November 1981 with a master's degree in pharmacology of traditional Chinese medicine.

Non-executive Directors

Mr. YOUNG Wai Po, Peter (楊惠波) (formerly known as Mr. YOUNG Wai Po (楊惠波)), aged 70, is our non-executive Director and a Controlling Shareholder. Mr. YOUNG is one of the co-founders of our Group. He was appointed as our Director with effect from 24 December 2012. Mr. YOUNG is also a director of GZ Consun, Consun (Inner Mongolia) and Kangyuan, respectively.

DIRECTORS AND SENIOR MANAGEMENT

Mr. YOUNG has over 30 years of experience in enterprise management and investments, during which he established a number of companies carrying on businesses in the areas of travel and pharmaceutical products. Mr. YOUNG invested in Sunflower Travel Service Limited and Sunflower Air-Freight (Hong Kong) Limited in mid-70s and has served as the directors of both companies since December 1976 and September 1977, respectively. After years of growth and development, Sunflower Travel Service Limited has become one of the leading travel agents in Hong Kong. Leveraging on his past successful experience in growing and developing a business, Mr. YOUNG co-founded GZ Consun in December 1997 and served as its chairman until November 2012.

Mr. YOUNG was once the director of Zhuhai Special Economic Zone Fangzhou Pharmaceutical Technology Development Co., Ltd., a company incorporated in the PRC. The business license of this company was revoked by Zhuhai City Administration of Industry and Commerce on 29 September 2003 due to the failure of the shareholders to make further capital conduction after the first installment thereof.

Mr. WANG Shunlong (王順龍), aged 49, is our non-executive Director and joined our Group in June 2008. He was appointed as our Director with effect from 24 December 2012. Mr. WANG is also a director of a number of our subsidiaries, including GZ Consun, Kangyuan, Brilliant Reach, Century International, Grand Reach and Immense Value.

Mr. WANG has over 16 years of experience in finance, investment and enterprise management. Mr. WANG currently serves as the managing director of Hony Capital Limited. He also serves as an executive director of 石藥集團有限公司 (CSPC Pharmaceutical Group Limited) (formerly known as 中國製藥集團有限公司 (China Pharmaceutical Group Limited)) which is mainly engaged in pharmaceutical product development, production and sale and listed on the Stock Exchange (stock code: 1093). From September 1995 to May 1997, Mr. WANG served successively as sales manager and assistant general manager in 航科技術開發有限公司 (CASIL Research & Development Co., Ltd.). Between May 1997 and December 2004, he worked at 上海實業醫藥科技(集團)有限公司 (SIIC Medical Science and Technology (Group) Ltd.) whereas his last position was head of strategic department. Between 31 July 2003 and 5 October 2010, Mr. Wang served as an independent non-executive Director of MRC Holdings Limited (now known as 中裕燃氣控股有限公司 Zhongyu Gas Holdings Limited), a company which was listed on the Growth Enterprise Market of the Stock Exchange (the then stock code: 8070) and has been transferred to the Main Board of the Stock Exchange (current stock code: 3633). Mr. WANG joined Hony Capital Limited in January 2005 as a director and was promoted to managing director in December 2007.

Mr. WANG graduated from 清華大學 (Tsinghua University) in July 1985 with a bachelor's degree in engineering and subsequently in April 1991 with a doctorate degree in engineering.

Mr. WANG once served as the chairman of the board of directors of 海南先毅藥物研究有限公司 (Hainan Xianyi Pharmaceutical Research Co., Ltd.), a company incorporated in the PRC. Since this company no longer carried on business and did not conduct the annual inspection, its business license was revoked by 海南省工商行政管理局 (Hainan Province Administration of Industry and Commerce) in February 2011. To the best of Mr. WANG's knowledge, information and belief and having made all reasonable enquiry, Mr. WANG confirmed that there is no contingent liabilities in respect of the above company and the revocation of its business licence. As confirmed by our PRC Legal Advisers, Mr. WANG has no contingent liability in respect of the revocation of business license of above company.

Mr. WANG Zi Han (王紫翰) (formerly known as Mr. WONG Zi Han (王紫翰)), aged 59, is our non-executive Director and joined our Group in June 2008. He was appointed as our Director with effect from 24 December 2012. Mr. WANG is also a director of GZ Consun and Kangyuan.

DIRECTORS AND SENIOR MANAGEMENT

Mr. WANG has accumulated over 15 years of experience in enterprise management. He has served as a director of Zijing since July 2011. From May 1992 to August 1999, Mr. WANG served successively as a deputy general manager, general manager and director of 深圳華源實業股份有限公司 (Shenzhen Huayuan Industrial Co., Ltd.) (now known as 沙河實業股份有限公司 (Shahe Industrial Co., Ltd.)), a company listed on the Shenzhen Stock Exchange (stock code: 000014). Mr. WANG served as a director and chairman in 深圳市海得威生物科技有限公司 (Shenzhen Haidewei Biotechnology Co., Ltd.) (now known as 深圳市中核海得威生物科技有限公司 (Shenzhen Zhonghe Haidewei Biotechnology Co., Ltd.) from September 2000 to February 2007. Between February 2001 and March 2003, he concurrently served as a director of Zijing.

Mr. WANG graduated from 蘭州大學 (Lanzhou University) in July 1983 with a bachelor's degree in history. He subsequently obtained a master's degree in engineering at 浙江大學 (Zhejiang University) in December 1992.

Independent non-executive Directors

Mr. SU Yuanfu (蘇元福), aged 67, is our independent non-executive Director. He joined our Group on 2 December 2013 when he was appointed as an independent non-executive Director.

Mr. SU graduated from 中國人民解放軍第四軍醫大學 (the Fourth Military Medical University of the People's Liberation Army of the PRC) in December 1969 and obtained a master's degree in radiopathology at the same university in December 1982. Mr. SU served various positions at the People's Liberation Army of the PRC. From January 1970 to August 1979, he served as a doctor at 西藏軍區總醫院 (General Hospital of Tibet Military Region). Between January 1984 and November 1995, Mr. SU served as the director of science and research office, the dean of academic affairs, the deputy superintendent and superintendent of the first affiliated hospital respectively at the Fourth Military Medical University of the People's Liberation Army of the PRC. From November 1995 to June 1998, he served as the director general of 總後勤部衛生部科訓局 (Technology Training Bureau of the Department of Health of the General Logistics Department). Between June 1998 and June 2004, Mr. SU served as the director of the department of medical administration and the deputy superintendent respectively at 解放軍總醫院 (the General Hospital of the People's Liberation Army). Mr. SU has been a standing director of 中國醫院協會 (Chinese Hospital Association) since October 2004.

Mr. FENG Zhongshi (馮仲實), aged 54, is our independent non-executive Director. He joined our Group on 2 December 2013 when he was appointed as an independent non-executive Director.

Mr. FENG is a lawyer qualified in the PRC. He is currently a partner of 北京市高界律師事務所 (Beijing Gao Jie Law Firm). He graduated from 中國政法大學 (China University of Political Science and Law) in July 1986 with a bachelor's degree in law. From July 1986 to January 1993, Mr. FENG worked at 內蒙古自治區司法廳 (the Department of Justice of Inner Mongolia Autonomous Region). He served as a lawyer at 內蒙古經濟律師事務所 (Inner Mongolia Jingji Law Office) (now known as 經世律師事務所 (Jingshi Law Office)) from 1993 to 1995. Between 1996 and 2002, Mr. FENG served as a partner at 內蒙古慧聰律師事務所 (Inner Mongolia Huicong Law Office). From 1996 to 2003, he also served as the head of legal department of 北京慧聰國際資訊有限國內公司 (Beijing Hui Cong International Information Co., Ltd.). Between 2002 and 2009, Mr. FENG served as a lawyer of 北京市中瑞律師事務所 (Beijing Zhong Rui Law Firm). Between June 2011 and January 2013, he served as a partner of 北京市金勵律師事務所 (Beijing Jin Li Law Firm).

Mr. FENG once served as a supervisor of 蘭州慧聰廣告有限公司 (Lanzhou Huicong Advertising Co., LTD) and 合肥市慧聰信息諮詢有限責任公司 (Hefei Huicong Information Consultation Co., Ltd.), both of which were incorporated in the PRC. Since the two companies no

DIRECTORS AND SENIOR MANAGEMENT

longer carried on business and did not conduct the annual inspection, their business licenses were revoked by 蘭州市工商行政管理局 (Lanzhou City Administration of Industry and Commerce) in December 2003 and by 合肥市工商行政管理局 (Hefei City Administration of Industry and Commerce) in September 2005, respectively.

Ms. CHENG Xinxin (成欣欣), aged 60, is our independent non-executive Director. She joined our Group on 2 December 2013 when she was appointed as an independent non-executive Director.

Ms. CHENG is a senior accountant recognised by 廣東省人事廳 (Guangdong Province Human Resource Department). She has been a registered financial planner since September 2002, a member of the Association of Certified Business Administrators of the United Kingdom since March 2005, a member of the Chinese Institute of Certified Public Accountants since October 1994 and a fellow of the Institute of Public Accountants of Australia since December 2004. Ms. CHENG graduated from 暨南大學 (Jinan University) majoring in trade economy in July 1985. Ms. CHENG obtained a master's degree in business administration from Murdoch University in March 2000 and obtained a doctor of philosophy degree by distance learning from a joint degree programme with European University of Ireland, University of International Business and Economics and Institute of Cost and Executive Accountants in March 2005.

Ms. CHENG has been a director of 康元國際管理有限公司 (Kang Yuan International Consultant Limited) since November 2000, a director and president of 廣州萬方興泰顧問有限公司 (Allwell Company Limited) since February 2002, a director of 長城保險經紀有限公司 (Chang Cheng Insurance Brokers Limited) since June 2003, the chairman of 廣州市越秀區珠江文化教育培訓中心 (Pearl River Training Centre) since October 2003, a director of 廣州賽寶聯睿信息科技有限公司 (Guangzhou Saibao Lianrui Information Technology Company Limited) since November 2003 and the principal partner of 廣州興泰會計師事務所 (Guangzhou Xingtai Accounting Firm) since March 2005. From November 1994 to January 2001, Ms. CHENG successively served as a deputy general manager in the department of enterprise management, financial department and department of strategic development of 香港粵海企業集團公司 (Yuehai Enterprise Group Company). She served as a deputy general manager of 香港飛龍國際投資有限公司 (Flying Dragon International Investment Limited) between April 1993 and November 1994. Ms. CHENG served various positions, such as deputy section chief, section chief and deputy director of 廣東省財政廳 (Department of Finance of Guangdong Province) from July 1975 to April 1993. From May 2002 to May 2008, Ms. CHENG served as an independent director of 廣東電力發展股份有限公司 (Guangdong Electric Power Development Co. Ltd.), a company listed on Shenzhen Stock Exchange (stock code: 000539).

Save as disclosed, each of our Directors has not been a director of any other publicly listed company during the three years preceding the date of this prospectus.

Save as disclosed herein, to the best of the knowledge, information and belief of our Directors having made all reasonable enquiries, there was no other matter with respect to the appointment of our Directors that needs to be brought to the attention of the Shareholders and there was no information relating to our Directors that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules as at the Latest Practicable Date.

SENIOR MANAGEMENT

Ms. LI Qian (黎倩), aged 48, is our executive Director and chief executive officer. Biographical details of Ms. LI are set out in the paragraph headed "Directors" under this section.

Mr. GAO Haien (高海恩), aged 44, is our Board secretary and the board secretary of GZ Consun. Mr. GAO joined our Group in August 2007 as the board secretary of GZ Consun. Mr. GAO has been the legal representative of GZ Consun, Consun (Inner Mongolia) and Kangyuan since March 2013.

DIRECTORS AND SENIOR MANAGEMENT

Prior to joining our Group, Mr. GAO successively served as a general manager of the accessories store and the assistant to headquarter general manager of 深圳市新亞工具連鎖店有限公司 (Shenzhen Sunyes Tools Co. Ltd.) from January 2006 to August 2007. Between July 1995 and January 2006, Mr. GAO successively served as a senior engineer of 萬威電子文儀廠 (IDT Data System Factory) and a technology manager of 深圳市奧美迪數碼科技有限公司 (Shenzhen Aomeidi Digital Technology Co. Ltd.).

Mr. GAO graduated from 中國礦業大學 (China University of Mining and Technology) in July 1992 with a bachelor degree in engineering and subsequently obtained a bachelor degree in economics at the same university in January 1994. He obtained a master's degree in business administration at 中南財經政法大學 (Zhongnan University of Economics and Law) in June 2012. Mr. GAO holds 證券業專業水平級別證書(二級) (Professional Certificate in Securities (Band II)) granted by 中國證券業協會 (Securities Association of China) and 董事會秘書資格證書 (Board Secretary Certificate) granted by the Shenzhen Stock Exchange. He is also a member of Hong Kong Securities and Investment Institute.

Mr. TANG Ning (唐寧), aged 47, is a vice president of GZ Consun. He has been the vice president of GZ Consun since June 2011. Mr. TANG joined our Group in July 1998 as a business manager. Between July 1998 and June 2011, Mr. TANG served various positions at GZ Consun, such as business manager, regional marketing manager, marketing director, and president assistant. Prior to joining our Group, Mr. TANG worked at 慈利縣百紡總公司 (Cili Baifang General Company Limited) between October 1987 and June 1998.

Mr. TANG graduated from 湖南商學院 (Hunan University of Commerce) in June 1986 majoring in marketing.

Mr. ZHOU Shangwen (周尚文), aged 43, is a vice president of GZ Consun. He has been the vice president of GZ Consun since July 2013. Mr. ZHOU joined our Group in April 2004 as a marketing manager for Guangdong province. Between April 2004 and September 2011, Mr. ZHOU served various positions at GZ Consun, such as regional marketing manager, marketing director for our kidney drugs and president assistant. Prior to joining our Group, Mr. ZHOU worked at 廣州市腦科醫院 (Guangzhou Brain Hospital) between July 1995 and March 1997. Between August 1997 and April 2004, Mr. ZHOU successively worked at 施維雅(天津)製藥有限公司 (Servier (Tianjin) Pharmaceutical Co., Ltd.).

Mr. ZHOU graduated from 北京醫科大學 (Beijing Medical University) (now known as 北京大學醫學部 (Peking University Health Science Center)) in July 1995 with a bachelor's degree in mental health.

Mr. YAO Bihua (姚畢華), aged 49, is the chief engineer of GZ Consun and concurrently serving as general manager of Kangyan and Consun (Inner Mongolia). Mr. YAO is primarily responsible for production management of our Group. Since Mr. YAO joined our Group in April 2007, he has served various positions, such as deputy general manager of GZ Consun and production director of our Group. Prior to joining our Group, Mr. YAO successively served as workshop director, engineer and chief engineer in 岳陽製藥一廠 (Yueyang First Pharmaceutical Factory) (now known as 岳陽中湘康神藥業集團有限公司 (Yueyang Zhongxiang Kangshen Pharmaceutical Group Company Limited)) between July 1986 and February 2004. From February 2004 to June 2005, he served as the production and technology director of 湖南津津製藥有限公司 (Hunan Jinjin Pharmaceutical Co., Ltd.). From September 2005 to April 2007, Mr. YAO served as the production and technology director and executive general manager respectively at 湖南和瑞生物科技有限公司 (Hunan Herui Biotechnology Company Limited). Between June 2006 and April 2007, he concurrently served as the vice president for production and technology at 湖南德瑞生物產業集團有限公司 (Hunan Derui Bio-industry Group Company Limited).

DIRECTORS AND SENIOR MANAGEMENT

Mr. YAO graduated from 湖南中醫學院 (Hunan Institute of Chinese Medicine) in July 1986 with a bachelor's degree in Chinese medicine. He is also a senior engineer (高級工程師) recognised by 湖南省人事廳 (Hunan Province Human Resource Department) and a licenced pharmacist (執業藥師) in the PRC.

Mr. YAU Chi Ming (丘志明), aged 46, has been the chief financial officer and our company secretary since he joined our Group in March 2013. Mr. YAU is responsible for our finance and accounting affairs and our company secretarial matters of our Group and he has over 18 years of experience in finance and accounting. Mr. YAU is an independent non-executive Director of G-Prop (Holdings) Limited, a company listed on the Stock Exchange (stock code: 286). Prior to joining our Group, he worked at an international audit firm since May 1995 and served as a partner since July 2007. Mr. YAU graduated from The University of Hong Kong in December 1992 with a bachelor's degree in social sciences. Mr. YAU is a fellow of the Hong Kong Institute of Certified Public Accountants.

Save as disclosed, each of the senior management has not been a director of any other publicly listed company during the three years preceding the date of this prospectus.

COMPANY SECRETARY

Mr. YAU Chi Ming (丘志明), aged 46, is our company secretary and chief financial officer. Biographical details of Mr. YAU are set out in the paragraph headed "Senior Management" under this section.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Our Company complies or intends to comply with the Corporate Governance Code in Appendix 14 to the Listing Rules, including but not limited to code provision A.4, which provides that there should be plans in place for orderly succession for appointments of new directors. Our three Board members, namely Mr. AN Yubao, Professor ZHU Quan and Mr. YOUNG Wai PO, Peter, are over 70 years old. Our Company has established succession planning to ensure a smooth transition of our Board, in particular, our executive directors, in the future.

Mr. AN Yubao and Ms. LI Qian have been the key leadership figures of our Group since the establishment of GZ Consun. Both of them have been primarily involved in formulating and implementing our corporate strategies and overseeing our overall business development and operation. Ms. LI Qian also leads a core management team comprising Professor ZHU Quan, our executive Director and the chief scientist of GZ Consun, Mr. TANG Ning, the vice president of GZ Consun, Mr. ZHOU Shangwen, the vice president of GZ Consun and three other senior management. Our Directors consider that Ms. LI Qian will be the best candidate to succeed Mr. AN Yubao as our chairman.

Save as our Board, our management team also consists of Mr. GAO Haien, being the board secretary of GZ Consun, Mr. TANG Ning, being the vice president of GZ Consun, Mr. ZHOU Shangwen, being the vice president of GZ Consun, Mr. YAO Bihua, being the chief engineer of GZ Consun and general manager of both Kangyuan and Consun (Inner Mongolia), Mr. YAU Chi Ming, being the chief financial officer and our company secretary, and various departmental directors. Our Directors consider that each of them will be a potential candidate to succeed Professor ZHU Quan as our executive Director. Professor ZHU Quan is primarily responsible for the product research and development of our Group. Professor ZHU Quan leads our in-house research and development team with the assistance of Dr. ZHENG Zhaoguang, who is the deputy general manager of Consun Research and has six years of experience in the research and development of

DIRECTORS AND SENIOR MANAGEMENT

medicines. Our Directors consider that Dr. ZHENG Zhaoguang will be the ideal candidate to succeed Professor ZHU Quan to lead our in-house research and development team.

As Mr. YOUNG Wai PO, Peter, one of our non-executive Directors, does not participate in the daily management of our Group, our Directors consider that it will not be difficult to recruit replacement personnel with equivalent qualifications to succeed Mr. YOUNG Wai PO, Peter as our non-executive Director.

BOARD COMMITTEE

Audit committee

Our Company established an audit committee on 2 December 2013 with its written terms of reference in compliance with the Listing Rules. The primary duties of the audit committee are to review and supervise our financial reporting process and internal control system, nominate and monitor external auditors and to provide advice and comments to our Board.

Our audit committee consists of three members, being Ms. CHENG Xinxin, Mr. WANG Shunlong and Mr. FENG Zhongshi. Ms. CHENG Xinxin currently serves as the chairman of our audit committee.

Remuneration committee

Our Company established a remuneration committee on 2 December 2013 with its written terms of reference in compliance with the code provisions of the Code on Corporate Governance Practices set out in Appendix 14 to the Listing Rules. The primary duties of the remuneration committee are to evaluate the performance and make recommendations on the remuneration of our senior management and to recommend members of our Board.

Our remuneration committee consists of three members, being Mr. FENG Zhongshi, Ms. LI and Mr. SU Yuanfu. Mr. FENG Zhongshi currently serves as the chairman of our remuneration committee.

Nomination committee

Our Company established a nomination committee on 2 December 2013 with its written terms of reference by reference to the code provisions of the Code on Corporate Governance Practices set out in Appendix 14 to the Listing Rules. The primary duties of the nomination committee are to make recommendations to our Board regarding candidates to fill vacancies on our Board and/or in senior management.

Our nomination committee consists of three members, being Mr. SU Yuanfu, Mr. AN and Ms. CHENG Xinxin. Mr. SU Yuanfu currently serves as the chairman of our nomination committee.

DIRECTORS AND SENIOR MANAGEMENT

COMPLIANCE ADVISER

Our Company has appointed Messis Capital Limited as our compliance adviser pursuant to Rule 3A.19 of the Listing Rules. Pursuant to Rule 3A.23 of the Listing Rules, our Company will consult the compliance adviser in the following circumstances:

- (1) before the publication of any regulatory announcement, circular or financial report;
- (2) where a transaction, which might be a notifiable or connected transaction, is contemplated including but not limited to share issues and share repurchases;
- (3) where our Company proposes to use the proceeds of the Global Offering in a manner different from that detailed in this prospectus or where the business activities, developments or results of operation of our Group deviate from any forecast, estimate, or other information in this prospectus; and
- (4) where the Stock Exchange makes an inquiry of our Company regarding unusual movements in the price or trading volume of the Shares.

The term of appointment of the compliance adviser shall commence on the Listing Date and end on the date on which our Company complies with Rule 13.46 of the Listing Rules in respect of its financial results for the first full financial year commencing after the Listing Date and such appointment may be subject to extension by mutual agreement.